BioSante Pharmaceuticals Announces Presentation/Webcast at the BIO CEO & Investor Conference
LINCOLNSHIRE, Illinois (February 12, 2007) – BioSante Pharmaceuticals, Inc. (AMEX: BPA) today announced that Stephen M. Simes, president and chief executive officer, will present at the 9th Annual BIO CEO & Investor Conference being held at the Waldorf-Astoria in New York, February 12-14, 2007. Mr. Simes’ presentation will take place at 12:45 am EST on February 14, 2007.
About BIO CEO Conference
The 9th Annual BIO CEO & Investor Conference will provide a neutral forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts will have the opportunity to shape the future investment landscape of the biotechnology industry. Hosted by the Biotechnology Industry Organization (BIO), the largest industry organization focused exclusively on biotechnology, the BIO CEO & Investor Conference will feature issue-oriented plenary sessions, educational sessions focused on hot technologies, therapeutics and key business issues, company presentations, one-on-one meetings, and networking opportunities.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante’s lead products include Elestrin™ (estradiol gel), developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel® (transdermal testosterone gel), now in a Phase III clinical trial, for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion.
The transdermal gel formulations used in the women’s gel products are licensed by BioSante from Antares Pharma. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration. Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.